Amylin Pharmaceuticals Inc - Current report filing (8-K)
December 07 2007 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 5, 2007
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or Other
Jurisdiction of
Incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
9360
Towne Centre Drive
|
San
Diego, California 92121
|
(Address of
principal executive offices and zip code)
|
|
|
Registrants
telephone number, including area code:
(858) 552-2200
|
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF
240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December 5,
2007, the Compensation and Human Resources Committee of the Board of Directors
of Amylin Pharmaceuticals, Inc. adopted Amylins executive cash bonus plan for
2008, or the Plan. The Plan is not
contained in a formal written document, but a summary of the manner in which
executive officer cash bonuses are determined is set forth below.
Amylins executive
officers are entitled to earn cash bonus compensation based upon the
achievement of certain specified corporate goals established by Amylins Board
of Directors. The corporate goals
established for fiscal year 2008 for purposes of the Plan relate to product
revenue and research and development results.
Under the Plan,
each participants target bonus is established by multiplying such participants
salary by a percentage value. The
percentage value for each executive officer is based on the participants level
of responsibility within the company.
Following the end
of the year, the Board determines whether the pre-established corporate goals
were attained. Based on this assessment,
the Compensation and Human Resources Committee awards each participant a cash bonus
equal to such participants target bonus multiplied by the percentage to which
the pre-established corporate goals were attained or exceeded. The Compensation and Human Resources
Committee retains the discretion to determine that a participant will receive a
cash bonus in an amount less than or greater than the amount earned by such
participant under the Plan.
Item
8.01. Other Events.
On December 6, 2007, Amylin Pharmaceuticals, Inc. issued a press
release announcing results from a 24-week
study of monotherapy, or stand-alone, BYETTA (exenatide) injection taken
twice daily in drug-naïve patients with type 2 diabetes. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
|
Exhibits.
|
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press release issued by Amylin on December 6, 2007.
|
|
|
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
|
AMYLIN PHARMACEUTICALS, INC.
|
Dated: December
7, 2007
|
By:
|
/s/ LLOYD A. ROWLAND
|
|
|
Lloyd A. Rowland
|
|
|
Vice President, Governance and
Compliance, and
Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
99.1
|
|
Press release issued by Amylin on December 6, 2007.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024